PHIO Phio Pharmaceuticals Corp

$PHIO This stock is just a matter of time. This new revolutionary technology will change how skin cancer is treated. No cutting the skin is huge and will be utilized around the world.

$PHIO dilute dilute dilute I feel like I’m in chemistry lab at the university of nebraska again

$PHIO adds 1.5million shares to its employee incentive plan effectively diluting share holders by 13 percent. This from a company that is already overvalued. I would expect some downward price movement. Even more reason to be BEARISH in the short run.

$PHIO little competition if Phio gets going onto pivotal phase for its lead drug as Sirnaomics appears to have de-prioritised its STP705 for oncology.

$PHIO The HTB flag is the most interesting thing on this screen. "HTB" next to the quote means PHIO is currently Hard To Borrow — brokers are having trouble locating shares for short sellers. That's meaningful: when a stock goes hard-to-borrow, it usually means existing short sellers are either stuck holding their positions (can't easily add to shorts) or new shorts can't get in cheaply. Combined with a stock that's been beaten down for a long stretch, an HTB flag raises the odds of a short squeeze if any real buying pressure shows up — fewer sellers available to press it back down. This is exactly the kind of technical fuel that could make your "violent move once it goes" thesis play out faster than fundamentals alone would suggest.

$PHIO It’s just a matter of time with this stock. I’ve been building my position for almost a year now when smart money started building their positions. Now I’m just buying at a discount as the impatient holders get bored or panic sell. This stock is going to be a runner.

$PHIO not exactly true that direct injection into tumors does not prevent or treat metastasis as the below explained:

$PHIO Everything is solid with PHIO so far. Following some of milestones tasks are pending with PHIO: 1) FDA Approval by the end of OCT-2026. 2) P2B starting date (before the 1st QTR of 2027). 3) Generate money from Warrants (above $2) to increase the cash flow and not to worry for the next two years and to avoid further dilution. 4) Improve the Marketing skills to take the next steps designed to advance the program toward its next stage of clinical development. Short term 14 pt plus Long term - Skyrocketing??? 🤞👍👌🤘

$PHIO so you want employees NOT to have any incentives or any stake that rewards them for continuously working on this project? Thats bad for morale. You want to invest in the employees and let them have something to look forward to.

$PHIO big pharma have largely overlooked on local injection of siRNA. But Phio Pharma's approach in local injection is noteworthy.

$PHIO Expected updates on Phase 1b clinical study of PH-762 in cutaneous squamous cell carcinoma (cSCC) this week.

$PHIO Catch 22 Scenarios: If FDA accepts and approves If Phase 2 B starts on time If large pharma interested in this UNIQUE siRNA technology Short term - 14 PT to 25 PT bagger minimum Long term 1 to 2 BIL value minimum - if Phase 2 B successfully completed In the meantime, just use the Warrants for the cash flow to avoid further dilution For a bigger Pharma to show interest, this needs to get out of this price range to $15 or $20 plus, likely to happen soon Time limit 2026Q4 to 2027Q1 Rest wait and watch, patience is KEY!

$PHIO We view today's PR as a modest but genuine de-risking event. More evidence that managment will steer PHIO to a binary event with a good likely hood of tremendous success. Not buyers down at these levels until a capital raise or partnership (partnership not very likely near term) removes the elephant in the room risk.

$PHIO more pointless chatter about value creation. It would be useful to see some actual value creation.

$PHIO my comments and analysis on 31 August now seem prescient . I remain bearish in the short run and bullish in the long run.

$PHIO 2 Form 4’s issued today, statement of changes in beneficial ownership. CEO has an additional 400k shares issued to him, for a new total of 764,861 shares, and CFO got an additional 108k shares, for a total of 189,112 shares..

$PHIO listed as neutral news but at least they ain't selling. "Three separate PHIO insiders — CEO Robert Bitterman, and directors Ronald Todd Plott and Patricia Bradford — have each made real, open-market stock purchases with their own money since late June, with Bradford's latest buy (12,000 shares) filed just today."